中基長壽科學(00767.HK)擬收購杭州臨安城南醫院部分股權
格隆匯 4 月 12日丨中基長壽科學(00767.HK)發佈公吿,2021年4月10日,公司與杭州臨安城南醫院有限公司(“杭州醫院”)簽訂諒解備忘錄,公司擬收購杭州醫院部分股權。董事會相信潛在收購可進一步完善集團全球長壽科學領域的佈局,長遠為集團帶來穩定、持續增長收入。
根據披露,杭州醫院是一家以二級標準建立的綜合性醫院,以高端體檢、重症康復、綜合醫療為特色。杭州醫院特設重症康復科,神經康復科,骨關節康復科,老年康復科,疼痛康復科及六大康復病區和遠程會診中心,腦促醒中心等。目前醫院開放牀位120張,在職職工122人,高級職稱與科主任有27人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.